Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.

@article{Lankford2012EfficacyAS,
  title={Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.},
  author={Alan Lankford and Roberta Rogowski and Beal Essink and Elizabeth Ludington and H Heith Durrence and Thomas Roth},
  journal={Sleep medicine},
  year={2012},
  volume={13 2},
  pages={133-8}
}
INTRODUCTION The efficacy and safety of doxepin (DXP), a histamine H(1) receptor antagonist, was evaluated in elderly adults with sleep maintenance insomnia. METHODS This was a randomized, double-blind, placebo-controlled outpatient trial. Elderly adults meeting DSM-IV-TR criteria for primary insomnia were randomized to four weeks of nightly treatment with either DXP 6 mg (N=130) or placebo (PBO; N=124). Efficacy was assessed using patient self-report instruments and clinician ratings… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Therapeutic rationale for low dose doxepin in insomnia patients

Jigar Katwala, Ananda K Kumar, Jaykumar J Sejpal, Marcelle Terrence, Manish K. Mishra
2013
View 9 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…